Targeting CFTR: How to treat cystic fibrosis by CFTR-repairing therapies

Current Drug Targets

Volumn 12, Issue 5, 2011, Pages 683-693

  Amaral, Margarida D ^a,b,c  

^a UNIVERSITY OF LISBON   (Portugal)

^b NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

Basic defect; CFTR modulator; Corrector; Drug discovery; F508del

Indexed keywords

AMILORIDE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANSAMYCIN DERIVATIVE; ATALUREN; CHAPERONE; COMPLEMENTARY DNA; DENUFOSOL; DIQUAFOSOL; FLAVONOID; GENISTEIN; PROTEIN INHIBITOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VORINOSTAT; VX 770;

CYSTIC FIBROSIS; DRUG EFFICACY; GENE MUTATION; GENE THERAPY; HUMAN; MEMBRANE CONDUCTANCE; NONHUMAN; NONSENSE MUTATION; PROTEIN HOMEOSTASIS; PROTEIN MODIFICATION; PROTEIN TARGETING; REVIEW;

ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DISCOVERY; FEMALE; GENE THERAPY; HUMANS; MALE; MICE; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN FOLDING;

EID: 79953300971     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011795378586     Document Type: Review

References (137)

1. Storey S, Wald G. Novel agents in cystic fibrosis. Nat Rev Drug Discov 2008; 7: 555-6.
2. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352: 1992-2001.
3. Accurso FJ. Update in cystic fibrosis 2005. Am J Respir Crit Care Med 2006; 173: 944-7.
4. Kerem B, Kerem E. The molecular basis for disease variability in cystic fibrosis. Eur J Hum Genet 1996; 4: 65-73.
5. De Boeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61: 627-35.
6. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-73.
7. Welsh MJ, Ramsey BW, Accurso FJ, et al. Cystic Fibrosis. Scriver CR, Beaudet AL, Sly WS, Valle D, Eds. The Metabolic Basis of Inherited Disease. 8th: 5121-5188. 2001. New York, McGraw-Hill.
8. Knowles MR, Stutts MJ, Spock A, et al. Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 1983; 221: 1067-70.
9. Mall M, Bleich M, Greger R, et al. The amiloride-inhibitable Na+ conductance is reduced by the cystic fibrosis transmembrane conductance regulator in normal but not in cystic fibrosis airways. J Clin Invest 1998; 102: 15-21.
10. Boucher RC. Regulation of airway surface liquid volume by human airway epithelia. Pflugers Arch 2003; 445: 495-8.
11. Amaral MD, Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 2007; 28: 334-241.
12. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 2008; 77:701-26.
13. The CFTR Mutation Database. http://wwwsickkidsonca/cftr2009.
14. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-80.
15. Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990; 63: 827-34.
16. Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992; 256: 774-9.
17. Bobadilla JL, Macek M, Jr., Fine JP, et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. Hum Mutat 2002; 19: 575-606.
18. The Molecular Genetic Epidemiology of Cystic Fibrosis. Report of a joint meeting of WHO/ECFTN/ICF(M)A/ECFS. Downloadable at: http://www.cfww.org/WHO_index.asp: World Health Organization; 2004.
19. Kerem E. Mutation specific therapy in CF. Paediatr Respir Rev 2006; 7 Suppl 1: S166-S169.
20. Noone PG, Knowles MR. 'CFTR-opathies': disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir Res 2001; 2: 328-32.
21. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73: 1251-4.
22. Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 1995; 29: 777-807.
23. Amaral MD. CFTR and chaperones: processing and degradation. J Mol Neurosci 2004; 23: 41-8.
24. Amaral MD, Pacheco P, Beck S, et al. Cystic fibrosis patients with the 3272-26A>G splicing mutation have milder disease than F508del homozygotes: a large European study. J Med Genet 2001; 38: 777-83.
25. Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994; 331: 974-80.
26. Amaral MD. Cystic Fibrosis-Translating Basic Science Knowledge into Therapies. US Respiratory Disease 2011, in press.
27. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349: 1433-41.
28. Rowe SM, Clancy JP. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development. BioDrugs 2009; 23: 165-74.
29. Goodier JL, Mayer J. PTC124 for cystic fibrosis. Lancet 2009; 373: 1426-7.
30. Nudelman I, Glikin D, Smolkin B, et al. Repairing faulty genes by aminoglycosides: Development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem 2010; [Epub ahead of print].
31. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115: 2564-71.
32. Results from phase IIa clinical trial of VX-809. http://www.cff.org2010.
33. Illek B, Fischer H, Santos GF, et al. cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein. Am J Physiol 1995; 268: C886-93.
34. Illek B, Zhang L, Lewis NC, et al. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol 1999; 277: C833-9.
35. Moran O, Zegarra-Moran O. A quantitative description of the activation and inhibition of CFTR by potentiators: Genistein. FEBS Lett 2005; 579: 3979-83.
36. Van GF, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009; 106: 18825-30.
37. Results from phase IIb clinical trial of VX-770. http://www.cff.org2009.
38. Kalin N, Claass A, Sommer M, et al. DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis. J Clin Invest 1999; 103: 1379-89.
39. Penque D, Mendes F, Beck S, et al. Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells. Lab Invest 2000; 80: 857-68.
40. Dalemans W, Barbry P, Champigny G, et al. Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 1991; 354: 526-8.
41. Wang F, Zeltwanger S, Hu S, et al. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels. J Physiol 2000; 524 Pt 3: 637-48.
42. Du L, Gatti RA. Progress toward therapy with antisense-mediated splicing modulation. Curr Opin Mol Ther 2009; 11: 116-23.
43. The CFTR2 Project (CFF). http://wwwgenetsickkidsonca/cftr/app2009.
44. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349: 1433-41.
45. Clancy JP, Rowe SM, Bebok Z, et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 2007; 37: 57-66.
46. Clunes MT, Boucher RC. Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis. Curr Opin Pharmacol 2008; 8: 292-9.
47. App EM, King M, Helfesrieder R, et al. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis 1990; 141: 605-12.
48. Tomkiewicz RP, App EM, Zayas JG, et al. Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration, and rheology of sputum. Am Rev Respir Dis 1993; 148: 1002-7.
49. Hirsh AJ, Zhang J, Zamurs A, et al. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl] butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2008; 325: 77-88.
50. Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med 2007; 13: 231-40.
51. Hughey RP, Mueller GM, Bruns JB, et al. Maturation of the epithelial Na+ channel involves proteolytic processing of the alpha-and gamma-subunits. J Biol Chem 2003; 278: 37073-82.
52. Hughey RP, Bruns JB, Kinlough CL, et al. Epithelial sodium channels are activated by furin-dependent proteolysis. J Biol Chem 2004; 279: 18111-4.
53. Planes C, Caughey GH. Regulation of the epithelial Na+ channel by peptidases. Curr Top Dev Biol 2007; 78: 23-46.
54. Sobczak K, Segal A, Bangel-Ruland N, et al. Specific inhibition of epithelial Na+ channels by antisense oligonucleotides for the treatment of Na+ hyperabsorption in cystic fibrosis. J Gene Med 2009; 11: 813-23.
55. Caci E, Melani R, Pedemonte N, et al. Epithelial sodium channel inhibition in primary human bronchial epithelia by transfected siRNA. Am J Respir Cell Mol Biol 2009; 40: 211-6.
56. Yueksekdag G, Drechsel M, Rossner M, et al. Repeated siRNA application is a precondition for successful mRNA gammaENaC knockdown in the murine airways. Eur J Pharm Biopharm 2010; [Epub ahead of print].
57. Thomas M, Lu JJ, Chen J, et al. Non-viral siRNA delivery to the lung. Adv Drug Deliv Rev 2007; 59: 124-33.
58. Yang YD, Cho H, Koo JY, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 2008; 455: 1210-5.
59. Caputo A, Caci E, Ferrera L, et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 2008; 322: 590-4.
60. Schroeder BC, Cheng T, Jan YN, et al. Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 2008; 134: 1019-29.
61. Kellerman D, Rossi MA, Engels J, et al. Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. Pulm Pharmacol Ther 2008; 21: 600-7.
62. Teichgraber V, Ulrich M, Endlich N, et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008; 14: 382-91.
63. Haggie PM, Verkman AS. Unimpaired lysosomal acidification in respiratory epithelial cells in cystic fibrosis. J Biol Chem 2009; 284: 7681-6.
64. Haggie PM, Verkman AS. Defective organellar acidification as a cause of cystic fibrosis lung disease: reexamination of a recurring hypothesis. Am J Physiol Lung Cell Mol Physiol 2009; 296: L859-L867.
65. Griesenbach U, Munkonge FM, Sumner-Jones S, et al. Assessment of CFTR function after gene transfer in vitro and in vivo. Methods Mol Biol 2008; 433: 229-42.
66. Davies LA, McLachlan G, Sumner-Jones SG, et al. Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes. Mol Ther 2008; 16: 1283-90.
67. Laner A, Goussard S, Ramalho AS, et al. Bacterial transfer of large functional genomic DNA into human cells. Gene Ther 2005; 12: 1559-72.
68. Rocchi L, Braz C, Cattani S, et al. E. coli cloned CFTR loci relevant for human artificial chromosome therapy. Hum Gene Ther 2010.
69. Denning GM, Ostedgaard LS, Welsh MJ. Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia. J Cell Biol 1992; 118: 551-9.
70. Amaral MD. Processing of CFTR: traversing the cellular maze--how much CFTR needs to go through to avoid cystic fibrosis? Pediatr Pulmonol 2005; 39: 479-91.
71. Farinha CM, Amaral MD. Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol Cell Biol 2005; 25: 5242-52.
72. Roxo-Rosa M, Xu Z, Schmidt A, et al. Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms. Proc Natl Acad Sci USA 2006; 103: 17891-6.
73. Yang Y, Janich S, Cohn JA, et al. The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc Natl Acad Sci USA 1993; 90: 9480-4.
74. Jiang C, Fang SL, Xiao YF, et al. Partial restoration of cAMP-stimulated CFTR chloride channel activity in DeltaF508 cells by deoxyspergualin. Am J Physiol 1998; 275: C171-8.
75. Sugawara A, Torigoe T, Tamura Y, et al. Polyamine compound deoxyspergualin inhibits heat shock protein-induced activation of immature dendritic cells. Cell Stress Chaperones 2009; 14: 133-9.
76. Farinha CM, Nogueira P, Mendes F, et al. The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. Biochem J 2002; 366: 797-806.
77. Loo MA, Jensen TJ, Cui L, et al. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. EMBO J 1998; 17: 6879-87.
78. Chang XB, Mengos A, Hou YX, et al. Role of N-linked oligosaccharides in the biosynthetic processing of the cystic fibrosis membrane conductance regulator. J Cell Sci 2008; 121: 2814-23.
79. Rosser MF, Grove DE, Chen L, et al. Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD) 1 and MSD2. Mol Biol Cell 2008; 19: 4570-9.
80. Glozman R, Okiyoneda T, Mulvihill CM, et al. N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic. J Cell Biol 2009; 184: 847-62.
81. Egan ME, Glockner-Pagel J, Ambrose C, et al. Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 2002; 8: 485-92.
82. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004; 304: 600-2.
83. 2+ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells. Traffic 2006; 7: 562-73.
84. Norez C, Noel S, Wilke M, et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 2006; 580: 2081-6.
85. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355: 1481-5.
86. Scott-Ward TS, Amaral MD. Deletion of Phe508 in the first nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator increases its affinity for the heat shock cognate 70 chaperone. FEBS J 2009; 276: 7097-109.
87. Hohfeld J, Cyr DM, Patterson C. From the cradle to the grave: molecular chaperones that may choose between folding and degradation. EMBO Rep 2001; 2: 885-90.
88. Cui L, Aleksandrov L, Hou YX, et al. The role of cystic fibrosis transmembrane conductance regulator phenylalanine 508 side chain in ion channel gating. J Physiol 2006; 572: 347-58.
89. Sharma M, Benharouga M, Hu W, et al. Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments. J Biol Chem 2001; 276: 8942-50.
90. Swiatecka-Urban A, Duhaime M, Coutermarsh B, et al. PDZ domain interaction controls the endocytic recycling of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 2002; 277: 40099-105.
91. Sharma M, Pampinella F, Nemes C, et al. Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol 2004; 164: 923-33.
92. Guidance for Industry, Investigators, and Reviewers. Exploratory IND Studies. US Department of Health and Human Services Food and Drug Administration.Center for Drug Evaluation and Research (CDER) 2006.
93. Balch WE, Morimoto RI, Dillin A, et al. Adapting proteostasis for disease intervention. Science 2008; 319: 916-9.
94. Powers ET, Morimoto RI, Dillin A, et al. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 2009; 78: 959-91.
95. Hutt DM, Powers ET, Balch WE. The proteostasis boundary in misfolding diseases of membrane traffic. FEBS Lett 2009; 583: 2639-46.
96. Kang MJ, Ryoo HD. Suppression of retinal degeneration in Drosophila by stimulation of ER-associated degradation. Proc Natl Acad Sci USA 2009; 106: 17043-8.
97. Sun F, Mi Z, Condliffe SB, et al. Chaperone displacement from mutant cystic fibrosis transmembrane conductance regulator restores its function in human airway epithelia. FASEB J 2008; 22: 3255-63.
98. Kim CP, Huan LJ, Gagnon S, et al. Functional rescue of DeltaF508-CFTR by peptides designed to mimic sorting motifs. Chem Biol 2009; 16: 520-30.
99. Bates E, Bode C, Costa M, et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 2008; 117: 886-96.
100. Saito K, Chen M, Bard F, et al. TANGO1 facilitates cargo loading at endoplasmic reticulum exit sites. Cell 2009; 136: 891-902.
101. Spang A. On vesicle formation and tethering in the ER-Golgi shuttle. Curr Opin Cell Biol 2009; 21: 531-6.
102. Brodsky JL, Wojcikiewicz RJ. Substrate-specific mediators of ER associated degradation (ERAD). Curr Opin Cell Biol 2009; 21: 516-21.
103. Younger JM, Ren HY, Chen L, et al. A foldable CFTR{Delta} F508 biogenic intermediate accumulates upon inhibition of the Hsc70-CHIP E3 ubiquitin ligase. J Cell Biol 2004; 167: 1075-85.
104. Lewis HA, Buchanan SG, Burley SK, et al. Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J 2004; 23: 282-93.
105. Lewis HA, Zhao X, Wang C, et al. Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. J Biol Chem 2005; 280: 1346-53.
106. Pissarra L, Farinha C, Schmidt A, et al. The Effect of F508del-NBD1 solubilizing mutations on processing of full-length CFTR. Pediatr Pulmonol 2006; 29S: Abs 47, 224-5.
107. Ford RC, Holzenburg A. Electron crystallography of biomolecules: mysterious membranes and missing cones. Trends Biochem Sci 2008; 33: 38-43.
108. Baker JM, Hudson RP, Kanelis V, et al. CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices. Nat Struct Mol Biol 2007; 14: 738-45.
109. Kanelis V, Hudson RP, Thibodeau PH, Thomas PJ, Forman-Kay JD. NMR evidence for differential phosphorylation-dependent interactions in WT and DeltaF508 CFTR. EMBO J 2010; 29: 263-77.
110. Hegedus T, Serohijos AW, Dokholyan NV, et al. Computational studies reveal phosphorylation-dependent changes in the unstructured R domain of CFTR. J Mol Biol 2008; 378: 1052-63.
111. Serohijos AW, Hegedus T, Riordan JR, et al. Diminished self-chaperoning activity of the DeltaF508 mutant of CFTR results in protein misfolding. PLoS Comput Biol 2008; 4: e1000008.
112. Wieczorek G, Zielenkiewicz P. DeltaF508 mutation increases conformational flexibility of CFTR protein. J Cyst Fibros 2008; 7: 295-300.
113. Serohijos AW, Hegedus T, Aleksandrov AA, et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci USA 2008; 105: 3256-61.
114. Moran O, Galietta LJ, Zegarra-Moran O. Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell Mol Life Sci 2005; 62: 446-60.
115. Wang X, Venable J, LaPointe P, et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006; 127: 803-15.
116. Trzcinska-Daneluti AM, Ly D, Huynh L, et al. High-content functional screen to identify proteins that correct F508del-CFTR function. Mol Cell Proteom 2009; 8: 780-90.
117. Galietta LJ, Haggie PM, Verkman AS. Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Lett 2001; 499: 220-4.
118. Lee AH, Iwakoshi NN, Anderson KC, et al. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA 2003; 100: 9946-51.
119. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783-92.
120. Hutt DM, Herman D, Rodrigues AP, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010; 6: 25-33.
121. Pepperkok R, Ellenberg J. High-throughput fluorescence microscopy for systems biology. Nat Rev Mol Cell Biol 2006; 7: 690-6.
122. Bansal M, Belcastro V, Ambesi-Impiombato A, et al. How to infer gene networks from expression profiles. Mol Syst Biol 2007; 3: 78.
123. Ma T, Thiagarajah JR, Yang H, et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 2002; 110: 1651-8.
124. Fulcher ML, Gabriel SE, Olsen JC, et al. Novel human bronchial epithelial cell lines for cystic fibrosis research. Am J Physiol Lung Cell Mol Physiol 2009; 296: L82-L91.
125. Wang XF, Reddy MM, Quinton PM. Effects of a new cystic fibrosis transmembrane conductance regulator inhibitor on Cl-conductance in human sweat ducts. Exp Physiol 2004; 89: 417-25.
126. Du M, Liu X, Welch EM, et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 2008; 105: 2064-9.
127. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87-91.
128. ®) in Nonambulatory Patients With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD). http://clinicaltrials.gov/ct2/show/NCT01009294.2010.
129. Hirtz S, Gonska T, Seydewitz HH, et al. CFTR Cl- channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis. Gastroenterology 2004; 127: 1085-95.
130. Snouwaert JN, Brigman KK, Latour AM, et al. An animal model for cystic fibrosis made by gene targeting. Science 1992; 257: 1083-8.
131. O'Neal WK, Hasty P, McCray PB, Jr., et al. A severe phenotype in mice with a duplication of exon 3 in the cystic fibrosis locus. Hum Mol Genet 1993; 2: 1561-9.
132. van Doorninck JH, French PJ, Verbeek E, et al. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J 1995; 14: 4403-11.
133. Lansdell KA, Kidd JF, Delaney SJ, et al. Regulation of murine cystic fibrosis transmembrane conductance regulator Cl- channels expressed in Chinese hamster ovary cells. J Physiol 1998; 512: 751-64.
134. Nadeau JH. Modifier genes in mice and humans. Nat Rev Genet 2001; 2: 165-74.
135. Rogers CS, Stoltz DA, Meyerholz DK, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 2008; 321: 1837-41.
136. Rogers CS, Hao Y, Rokhlina T, et al. Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer. J Clin Invest 2008; 118: 1571-7.
137. Ostedgaard LS, Rogers CS, Dong Q, et al. Processing and function of CFTR-DeltaF508 are species-dependent. Proc Natl Acad Sci USA 2007; 104: 15370-5.